Literature DB >> 24824247

Clinical features and outcomes of 210 patients with idiopathic pulmonary fibrosis.

Miaotian Cai1, Min Zhu2, Chengjun Ban2, Jin Su2, Qiao Ye2, Yan Liu2, Wen Zhao2, Chen Wang3, Huaping Dai4.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a lethal chronic interstitial lung disease (ILD) of unknown cause and having a variable and unpredictable course. This study aimed to summarize the clinical features and follow-up outcomes and to identify potential factors useful for the assessment of prognosis in IPF.
METHODS: Two hundred and ten patients hospitalized and diagnosed as IPF in our unit from January 1999 to June 2007 were enrolled into this study. The baseline demographic, clinical, radiologic and physiologic characteristics were summarized. Clinical follow-up data until February 2010 were collected, and the median survival time and 1-, 2-, and 5-year survival rates, as well as the influences of the summarized baseline variables on the prognosis were analyzed.
RESULTS: The age at diagnosis as IPF was (64 ± 10) years, the duration before diagnosis of 106 patients (50%) was shorter than 2 years, and 73% were males. One hundred and forty-five patients (69%) had a history of smoking with a median pack-year of 18. Eighty-nine patients (42%) had emphysema and 62 patients (29%) pulmonary arterial hypertension (PAH). One hundred and twenty-four patients were followed up, of which 99 patients died from various causes including respiratory failure related to IPF (93%). The follow-up period was (21 ± 23) months. The median survival time was 38 months. The 1-, 2-, and 5-year survival rates were 61%, 52%, and 39%, respectively. Multivariate analysis showed clubbing, PAH, duration from initial onset to diagnosis, and forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) were independent prognostic indicators of IPF.
CONCLUSION: IPF patients who have clubbing, PAH, a higher FEV1/FVC, and a short duration from initial onset to diagnosis have a poorer outcome.

Entities:  

Mesh:

Year:  2014        PMID: 24824247

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  10 in total

1.  Obstructive lung function decline and IPF: The dark face of the moon.

Authors:  Mauro Carone; Francesco G Salerno; Antonio M Esquinas
Journal:  Chron Respir Dis       Date:  2016-02-01       Impact factor: 2.444

2.  Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways.

Authors:  Jing Geng; Xiaoxi Huang; Ying Li; Xuefeng Xu; Shuhong Li; Dingyuan Jiang; Zheng Liu; Huaping Dai
Journal:  Exp Biol Med (Maywood)       Date:  2015-08-11

3.  Incidence and clinical characteristics of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Wei Yan; Li-Ying Peng; Cheng-Jun Ban; Xue-Feng Xu; Min Zhu; Yan Liu; Shu Zhang; Zhen-Guo Zhai; Chen Wang; Hua-Ping Dai
Journal:  Chin Med J (Engl)       Date:  2015-04-05       Impact factor: 2.628

4.  S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Yupeng Li; Yaowu He; Shibin Chen; Qi Wang; Yi Yang; Danting Shen; Jing Ma; Zhe Wen; Shangwei Ning; Hong Chen
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

Review 5.  Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Qiang Zheng; Ingrid A Cox; Julie A Campbell; Qing Xia; Petr Otahal; Barbara de Graaff; Tamera J Corte; Alan K Y Teoh; E Haydn Walters; Andrew J Palmer
Journal:  ERJ Open Res       Date:  2022-03-14

6.  Identification and validation of autophagy-related gene expression for predicting prognosis in patients with idiopathic pulmonary fibrosis.

Authors:  Guichuan Huang; Xin Xu; Chunrong Ju; Nanshan Zhong; Jianxing He; Xiao Xiao Tang
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

7.  Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis.

Authors:  Jing Geng; Xiaoxi Huang; Ying Li; Xuefeng Xu; Shuhong Li; Dingyuan Jiang; Jiurong Liang; Dianhua Jiang; Chen Wang; Huaping Dai
Journal:  Respir Res       Date:  2015-10-09

8.  Follistatin-Like 1 Promotes Bleomycin-Induced Pulmonary Fibrosis through the Transforming Growth Factor Beta 1/Mitogen-Activated Protein Kinase Signaling Pathway.

Authors:  Yan-Kun Jin; Xiao-He Li; Wang Wang; Jie Liu; Wei Zhang; Yin-Shan Fang; Zhi-Fei Zhang; Hua-Ping Dai; Wen Ning; Chen Wang
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

9.  Molecular pathogenesis involved in human idiopathic pulmonary fibrosis based on an integrated microRNA‑mRNA interaction network.

Authors:  Lijing Wang; Wei Huang; Lemeng Zhang; Qiong Chen; Hongjun Zhao
Journal:  Mol Med Rep       Date:  2018-09-05       Impact factor: 2.952

10.  Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study.

Authors:  Bingbing Xie; Yanhong Ren; Jing Geng; Xuan He; Chengjun Ban; Shiyao Wang; Dingyuan Jiang; Sa Luo; Qihang Chen; Min Liu; Ruie Feng; Ling Zhao; Huaping Dai; Chen Wang
Journal:  BMJ Open       Date:  2020-11-11       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.